CorMedix Inc. - Common Stock (CRMD)

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network.

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

DefenCath, CorMedix’s lead product, was launched in hospitals in April 2024 and in outpatient settings in July 2024 following FDA approval.

CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug.

CorMedix Inc (NASDAQ:CRMD) shares are hitting new 52-week highs on Monday after the company raised its sales guidance for the second quarter.

The company reported net revenue of $39.1 million for the first quarter from the sales of DefenCath, above an analyst estimate of $36, as per Finchat data.

The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78 million.

CRMD earnings call for the period ending December 31, 2024.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.

The company reported earnings of $0.22 per share compared with a loss of $0.26 per share in the corresponding period of 2023, owing to the launch of its lead product, DefenCath.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.